Similarly, dual PARP1-BRD4 inhibition enhances DNA damage response and anti-tumor activity in breast cancer, while sequential PARP and BET blockade synergistically suppresses glioblastoma growth (181, 182). Here, BRD4 is linked to breast cancer.